November 25 to 28, 2025, the 27th Pharmtech&Ingredients Exhibition — the most influential pharmaceutical industry event in Russia and Eurasia —was grandly held at the Crocus City International Exhibition Center in Moscow. As a core bridge connecting the global pharmaceutical industry with the Eurasian market, this exhibition gathers over 560 exhibitors from more than 20 countries worldwide and welcomes over 10,000 professional visitors, building an efficient platform for industry exchange and business cooperation.
Highlights of Xieli Participation
1. Core APIs Display
Focusing on the needs of the Eurasian market, this exhibition highlights a product matrix featuring natural active ingredient extracts and their derivatives, as well as advantages in specialized fully synthetic raw materials, including Ursodeoxycholic Acid (UDCA), Hesperidin, Diosmin, and a variety of oncology APIs. Among them:
Ursodeoxycholic Acid is refined using a patented REDOX process, complying with CP/EP international standards. It has completed registration certifications with the EDQM and multiple countries in the Eurasian region, garnering widespread attention for its stable quality and technological advantages;
Moxifloxacin Hydrochloride, a core raw material in the anti-infection field, has obtained certifications in multiple overseas markets and is tailored to meet the pharmaceutical production needs of the Eurasian region. Its strong technical capabilities have attracted in-depth consultations from numerous regional customers, fully demonstrating the company's R&D and production strengths as a high-tech enterprise.
2. Customized Services for the Eurasian Market
Customized Production: Flexibly responding to market demands, we offer customization services and simultaneous diversified packaging solutions to meet the cooperation scenarios of different customers;
Localized Support: Leveraging in-depth understanding of the Eurasian market, we provide registration application guidance and supporting services to simplify customers' market entry processes and optimize cooperation experiences.
3. International-level Technical Strength Guarantee
With international certifications such as FDA/ EU GMP/ Japanese GMP, Xieli's quality system has gained wide recognition in the Eurasian market. Meanwhile, equipped with flexible production lines, it can efficiently adapt to customized production needs. The production standards are fully in line with pharmaceutical industry regulatory requirements, providing a solid guarantee for the stable supply of products.
Exhibition Objectives
1. Deepen Existing Cooperation: Conduct in-depth negotiations with core partners in the Eurasian region, advance long-term supply cooperation, and continuously consolidate the foundation of regional cooperation;
2. Expand New Markets: Focus on deploying in Central Asia and surrounding regions with strong demand for APIs, explore potential cooperation opportunities, and expand market coverage;
3. Explore Innovative Applications: Collaborate with scientific research institutions and pharmaceutical enterprises in the Eurasian region to carry out cooperative R&D on new indications of plant extracts in fields such as chronic diseases and adjuvant tumor therapy, accurately meeting regional health needs.
Exhibition Conclusion
The 2025 Pharmtech&Ingredients Russia Exhibition has drawn to a successful close. Xieli would like to extend sincere gratitude to all new and long-standing partners who visited our booth. Throughout this exhibition, we engaged in fruitful exchanges with clients from the Eurasian region and across the globe, secured multiple cooperation intentions, and further solidified the company’s international competitiveness in the API sector. We firmly believe that by persisting in technological innovation and deepening our presence in the Eurasian market, Xieli will deliver even higher-quality API products and services to global clients, allowing pharmaceutical raw materials of "China’s Intelligent Manufacturing" to better benefit the people of all Eurasian countries.
